LEVETIRACETAM | N021505 | UCB INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Lachman Consultant Services, Inc. FDA-2026-P-2354 Lachman Consultant Services, Inc., on behalf of a client, filed a suitability petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting FDA approval to proceed with an Abbreviated New Drug Application for Levetiracetam Powder for Oral Solution in strengths of 250 mg, | Suitability | 2026-03-06 | Open | Lachman Consultant Services |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.